{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:52:49Z","timestamp":1787496769358,"version":"build-2736575974"},"reference-count":30,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12,1]]},"abstract":"<jats:p>OBJECTIVE: Pompe disease causes progressive, debilitating, and often life-threatening musculoskeletal, respiratory, and cardiac symptoms. Favorable outcomes with early intravenous enzyme-replacement therapy and alglucosidase alfa have been reported, but early clinical diagnosis before the development of severe symptoms has rarely been possible in infants.<\/jats:p>\n                  <jats:p>METHODS: We recently conducted a newborn screening pilot program in Taiwan to improve the early detection of Pompe disease. Six of 206088 newborns screened tested positive and were treated for Pompe disease. Five had the rapidly progressive form of Pompe disease, characterized by cardiac and motor involvement, and were treated soon after diagnosis. The sixth patient was started on treatment at 14 months of age because of progressive muscle weakness. Outcomes were compared with treated patients whose disease was diagnosed clinically and with untreated historical control subjects.<\/jats:p>\n                  <jats:p>RESULTS: At the time of this report, patients had been treated for 14 to 32 months. The 5 infants who had early cardiac involvement demonstrated normalization of cardiac size and muscle pathology with normal physical growth and age-appropriate gains in motor development. The infant without cardiac involvement also achieved normal motor development with treatment. Survival in patients who had newborn screening was significantly improved compared with those in the untreated reference cohort (P = .001). Survival in the treated clinical comparators was reduced but not statistically different from that in the newborn screening group (P = .48).<\/jats:p>\n                  <jats:p>CONCLUSIONS: Results from this study indicate that early treatment can benefit infants with Pompe disease and highlight the advantages of early diagnosis, which can be achieved by newborn screening.<\/jats:p>","DOI":"10.1542\/peds.2008-3667","type":"journal-article","created":{"date-parts":[[2009,11,30]],"date-time":"2009-11-30T07:27:49Z","timestamp":1259566069000},"page":"e1116-e1125","source":"Crossref","is-referenced-by-count":190,"title":["Pompe Disease in Infants: Improving the Prognosis by Newborn Screening and Early Treatment"],"prefix":"10.1542","volume":"124","author":[{"given":"Yin-Hsiu","family":"Chien","sequence":"first","affiliation":[{"name":"Departments of Pediatrics"},{"name":"Medical Genetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni-Chung","family":"Lee","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics"},{"name":"Medical Genetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth L.","family":"Thurberg","sequence":"additional","affiliation":[{"name":"Genzyme Corporation, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chuan","family":"Chiang","sequence":"additional","affiliation":[{"name":"Medical Genetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokui Kate","family":"Zhang","sequence":"additional","affiliation":[{"name":"Genzyme Corporation, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Keutzer","sequence":"additional","affiliation":[{"name":"Genzyme Corporation, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Chu","family":"Huang","sequence":"additional","affiliation":[{"name":"Medical Genetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Hwan","family":"Wu","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Hsin","family":"Huang","sequence":"additional","affiliation":[{"name":"Pathology, National Taiwan University Hospital and National Taiwan University School of Medicine, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuu-Jen","family":"Tsai","sequence":"additional","affiliation":[{"name":"Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Tsong","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Science, Academia Sinica, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics"},{"name":"Medical Genetics"},{"name":"Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2009,12,1]]},"reference":[{"key":"2021120905204144300_R1","unstructured":"Pompe JC. Concerning idiopathic hypertrophy of the heart [in Dutch]. Ned Tijdschr Geneeskd.\u20081932;76:304\u2013311"},{"key":"2021120905204144300_R2","unstructured":"Hirschhorn R. Glycogen storage disease type II: acid alpha-glucosidase (acid maltose) deficiency. In: Scriver CR, ed. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:3389\u20133420"},{"key":"2021120905204144300_R3","unstructured":"Bashan N, Potashnik R, Barash V, Gutman A, Moses SW. Glycogen storage disease type II in Israel. Isr J Med Sci.\u20081988;24(4\u20135):224\u2013227"},{"key":"2021120905204144300_R4","unstructured":"Lin CY, Shieh JJ. Molecular study on the infantile form of Pompe disease in Chinese in Taiwan. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi.\u20081996;37(2):115\u2013121"},{"key":"2021120905204144300_R5","doi-asserted-by":"crossref","unstructured":"Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr.\u20082006;148(5):671\u2013676","DOI":"10.1016\/j.jpeds.2005.11.033"},{"key":"2021120905204144300_R6","doi-asserted-by":"crossref","unstructured":"van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics.\u20082003;112(2):332\u2013340","DOI":"10.1542\/peds.112.2.332"},{"key":"2021120905204144300_R7","doi-asserted-by":"crossref","unstructured":"Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid alpha-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology.\u20082007;68(2):99\u2013109","DOI":"10.1212\/01.wnl.0000251268.41188.04"},{"key":"2021120905204144300_R8","doi-asserted-by":"crossref","unstructured":"Nicolino M, Byrne B, Wraith JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med.\u20082009;11(3):210\u2013219","DOI":"10.1097\/GIM.0b013e31819d0996"},{"key":"2021120905204144300_R9","doi-asserted-by":"crossref","unstructured":"Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial. Genet Med.\u20082001;3(2):132\u2013138","DOI":"10.1097\/00125817-200103000-00008"},{"key":"2021120905204144300_R10","doi-asserted-by":"crossref","unstructured":"van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics.\u20082004;113(5). Available at: www.pediatrics.org\/cgi\/content\/full\/113\/5\/e448","DOI":"10.1542\/peds.113.5.e448"},{"key":"2021120905204144300_R11","doi-asserted-by":"crossref","unstructured":"Chien YH, Chiang SC, Zhang XK, et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics.\u20082008;122(1). Available at: www.pediatrics.org\/cgi\/content\/full\/122\/1\/e39","DOI":"10.1542\/peds.2007-2222"},{"key":"2021120905204144300_R12","doi-asserted-by":"crossref","unstructured":"Kemper AR, Hwu WL, Lloyd-Puryear M, Kishnani PS. Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations. Pediatrics.\u20082007;120(5). Available at: www.pediatrics.org\/cgi\/content\/full\/120\/5\/e1327","DOI":"10.1542\/peds.2007-0388"},{"key":"2021120905204144300_R13","doi-asserted-by":"crossref","unstructured":"Lynch CM, Johnson J, Vaccaro C, Thurberg BL. High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology. J Histochem Cytochem.\u20082005;53(1):63\u201373","DOI":"10.1177\/002215540505300108"},{"key":"2021120905204144300_R14","doi-asserted-by":"crossref","unstructured":"Ko TM, Hwu WL, Lin YW, et al. Molecular genetic study of Pompe disease in Chinese patients in Taiwan. Hum Mutat.\u20081999;13(5):380\u2013384","DOI":"10.1002\/(SICI)1098-1004(1999)13:5<380::AID-HUMU6>3.0.CO;2-A"},{"key":"2021120905204144300_R15","unstructured":"Piper MC, Pinnell LE, Darrah J, Maguire T, Byrne PJ. Construction and validation of the Alberta Infant Motor Scale (AIMS). Can J Public Health.\u20081992;83(suppl 2):S46\u2013S50"},{"key":"2021120905204144300_R16","unstructured":"Folio MR, Fewell RR. Peabody Developmental Motor Scales, 2nd ed. (PDMS-2). Austin, TX: PRO-ED, Inc; 2000"},{"key":"2021120905204144300_R17","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc.\u20081958;53:457\u2013481","DOI":"10.1080\/01621459.1958.10501452"},{"key":"2021120905204144300_R18","unstructured":"Hwu WL, Chien YH, Lee NC, Chen CA, Wu MH. Elevation of BNP in newborns with hypertrophic cardiomyopathy due to Pompe disease. Heart. 2008. Available at: http:\/\/heart.bmj.com\/cgi\/eletters\/94\/10\/1307#8129. Accessed March 30, 2008"},{"key":"2021120905204144300_R19","doi-asserted-by":"crossref","unstructured":"Vogel M, Staller W, Buhlmeyer K. Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children. Pediatr Cardiol.\u20081991;12(3):143\u2013149","DOI":"10.1007\/BF02238520"},{"key":"2021120905204144300_R20","doi-asserted-by":"crossref","unstructured":"Thurberg BL, Lynch Maloney C, Vaccaro C, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest.\u20082006;86(12):1208\u20131220","DOI":"10.1038\/labinvest.3700484"},{"key":"2021120905204144300_R21","doi-asserted-by":"crossref","unstructured":"Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr.\u20082006;149(1):89\u201397","DOI":"10.1016\/j.jpeds.2006.02.035"},{"key":"2021120905204144300_R22","doi-asserted-by":"crossref","unstructured":"Schoser BG, Muller-Hocker J, Horvath R, et al. Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited. Neuropathol Appl Neurobiol.\u20082007;33(5):544\u2013559","DOI":"10.1111\/j.1365-2990.2007.00839.x"},{"key":"2021120905204144300_R23","doi-asserted-by":"crossref","unstructured":"Sarnat HB, Roth SI, Carroll JE, Brown BI, Dungan WT. Lipid storage myopathy in infantile Pompe's disease. Arch Neurol.\u20081982;39(3):180\u2013183","DOI":"10.1001\/archneur.1982.00510150050012"},{"key":"2021120905204144300_R24","doi-asserted-by":"crossref","unstructured":"Verity MA. Infantile Pompe's disease, lipid storage, and partial carnitine deficiency. Muscle Nerve.\u20081991;14(5):435\u2013440","DOI":"10.1002\/mus.880140509"},{"key":"2021120905204144300_R25","doi-asserted-by":"crossref","unstructured":"Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr.\u20082000;137(2):283\u2013285","DOI":"10.1067\/mpd.2000.107112"},{"key":"2021120905204144300_R26","doi-asserted-by":"crossref","unstructured":"Hagemans ML, Winkel LP, Hop WC, Reuser AJ, Van Doorn PA, Van der Ploeg AT. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology.\u20082005;64(12):2139\u20132141","DOI":"10.1212\/01.WNL.0000165979.46537.56"},{"key":"2021120905204144300_R27","doi-asserted-by":"crossref","unstructured":"Winkel LP, Hagemans ML, van Doorn PA, et al. The natural course of non-classic Pompe's disease: a review of 225 published cases. J Neurol.\u20082005;252(8):875\u2013884","DOI":"10.1007\/s00415-005-0922-9"},{"key":"2021120905204144300_R28","doi-asserted-by":"crossref","unstructured":"Van der Beek NA, Hagemans ML, Reuser AJ, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord.\u20082009;19(2):113\u2013117","DOI":"10.1016\/j.nmd.2008.11.007"},{"key":"2021120905204144300_R29","doi-asserted-by":"crossref","unstructured":"Li Y, Scott CR, Chamoles NA, et al. Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem.\u20082004;50(10):1785\u20131796","DOI":"10.1373\/clinchem.2004.035907"},{"key":"2021120905204144300_R30","doi-asserted-by":"crossref","unstructured":"Zhang XK, Elbin CS, Chuang WL, et al. Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin Chem.\u20082008;54(10):1725\u20131728","DOI":"10.1373\/clinchem.2008.104711"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/124\/6\/e1116\/1022193\/zpe012090e1116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/124\/6\/e1116\/1022193\/zpe012090e1116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T17:42:49Z","timestamp":1639071769000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/124\/6\/e1116\/72177\/Pompe-Disease-in-Infants-Improving-the-Prognosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,1]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2009,12,1]]},"published-print":{"date-parts":[[2009,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2008-3667","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,1]]}}}